KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Ratio (2020 - 2025)

Recursion Pharmaceuticals' Equity Ratio history spans 6 years, with the latest figure at 0.77 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 7.39% year-over-year to 0.77; the TTM value through Dec 2025 reached 0.77, up 7.39%, while the annual FY2025 figure was 0.77, 7.39% up from the prior year.
  • Equity Ratio reached 0.77 in Q4 2025 per RXRX's latest filing, up from 0.75 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q2 2021 to a low of 0.86 in Q1 2021.
  • Average Equity Ratio over 5 years is 0.66, with a median of 0.71 recorded in 2024.
  • Peak YoY movement for Equity Ratio: soared 228.76% in 2021, then crashed 30.24% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.89 in 2021, then fell by 22.13% to 0.69 in 2022, then rose by 2.34% to 0.71 in 2023, then increased by 0.76% to 0.71 in 2024, then rose by 7.39% to 0.77 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Equity Ratio are 0.77 (Q4 2025), 0.75 (Q3 2025), and 0.71 (Q2 2025).